Format

Send to

Choose Destination
Thromb Res. 2016 Apr;140:118-124. doi: 10.1016/j.thromres.2016.02.020. Epub 2016 Feb 18.

A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation.

Author information

1
Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, TN, USA.
2
Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, TN, USA; Department of Bioengineering and Organic Chemistry, Tomsk Polytechnic University, Tomsk, Russia.
3
Dyax Corp., Burlington, MA, USA.
4
Department of Molecular Medicine and Surgery, Karolinska Institutet and University Hospital, Stockholm, Sweden; Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
5
Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH, USA.
6
Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA.
7
Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, TN, USA. Electronic address: dave.gailani@vanderbilt.edu.

Abstract

Studies with animal models implicate the plasma proteases factor XIIa (FXIIa) and α-kallikrein in arterial and venous thrombosis. As congenital deficiencies of factor XII (FXII) or prekallikrein (PK), the zymogens of FXIIa and α-kallikrein respectively, do not cause bleeding disorders, inhibition of these enzymes may have therapeutic benefit without compromising hemostasis. The relative contributions of FXIIa and α-kallikrein to thrombosis in animal models are not clear. We compared mice lacking FXII or PK to wild type mice in established models of arterial thrombosis. Wild type mice developed carotid artery occlusion when the vessel was exposed to a 3.5% solution of ferric chloride (FeCl3). FXII-deficient mice were resistant to occlusion at 5% FeCl3 and partially resistant at 10% FeCl3. PK-deficient mice were resistant at 3.5% FeCl3 and partially resistant at 5% FeCl3. Mice lacking high molecular weight kininogen, a cofactor for PK activation and activity, were also partially resistant to thrombosis at 5% FeCl3. Induction of carotid artery thrombosis with Rose Bengal was delayed in FXII-deficient mice compared to wild type or PK-deficient animals. In human plasma supplemented with silica, DNA or collagen to induce contact activation, an antibody to the FXIIa active site was more effective at preventing thrombin generation than an antibody to the α-kallikrein active site. Similarly, the FXIIa antibody was more effective at reducing fibrin formation in human blood flowing through collagen coated-tubes. The findings suggest that inhibitors of FXIIa will have more potent anti-thrombotic effects than inhibitors of α-kallikrein.

KEYWORDS:

Factor XII; Factor XIIa; Prekallikrein; Thrombosis; α-Kallikrein

PMID:
26950760
PMCID:
PMC4821716
DOI:
10.1016/j.thromres.2016.02.020
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center